Proteinuria is a known AE occurring frequently in patients receiving anti-VEGF therapy, because of the suppression of nephrin, an important protein for the maintenance of the glomerular slit diaphragm.25 Our findings indicate that treatment with ramucirumab increases the risk of proteinuria in EA patients with cancer; however, proteinuria overall was of low-grade severity and did not lead to treatment discontinuation. This evidence concerns the gene VEGFA and Proteinuria.